البلد: أستراليا
اللغة: الإنجليزية
المصدر: Department of Health (Therapeutic Goods Administration)
pravastatin sodium, Quantity: 80 mg
Dr Reddys Laboratories Australia Pty Ltd
pravastatin sodium
Tablet, film coated
Excipient Ingredients: lactose monohydrate; microcrystalline cellulose; meglumine; crospovidone; magnesium stearate; croscarmellose sodium; titanium dioxide; hypromellose; macrogol 8000; purified talc
Oral
30 tablet, 100 tablet, 500 tablet, 90 tablet
(S4) Prescription Only Medicine
As an adjunct to diet for the treatment of hypercholesterolaemia. Prior to initiating therapy with pravastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated. Pravastatin-DRLA is indicated in patients with previous myocardial infarction including those who have normal (4.0 to 5.5 mmol/L) serum cholesterol levels. Pravastatin-DRLA is indicated in patients with unstable angina pectoris (see CLINICAL TRIALS). Pravastatin-DRLA is indicated as an adjunct to diet and lifestyle modification for the treatment of heterozygous familial hypercholesterolaemia in children and adolescent patients aged 8 years and older (see CLINICAL TRIALS).
Visual Identification: White, round, biconvex, coated tablets debossed "RDY" on one side and "274" on the other side; Container Type: Bottle; Container Material: HDPE; Container Life Time: 2 Years; Container Temperature: Store below 25 degrees Celsius
Licence status A
2010-10-28
Pravastatin-DRLA: CMI, V3, 10Nov10 Page 1 of 3 PRAVASTATIN-DRLA _Pravastatin sodium _ CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET This medicine your doctor has prescribed for you is called Pravastatin-DRLA. The information in this leaflet will answer some of the questions you may have about Pravastatin-DRLA. This leaflet does not tell you everything about Pravastatin-DRLA. Your doctor and pharmacist have been provided with full information and can answer any questions you may have. This leaflet is no substitute for talking with your doctor or pharmacist. You should follow all advice from your doctor when being treated with this medicine. This information is not intended to replace your doctor's advice. You should read this leaflet carefully before starting Pravastatin-DRLA and keep it in a safe place to refer to later. WHAT PRAVASTATIN- DRLA IS USED FOR Pravastatin-DRLA is used to treat people who have had a heart attack or an episode of unstable angina, or who have high blood cholesterol levels. In these people Pravastatin-DRLA can reduce the risk of further heart disease, reduce the possibility of needing a bypass operation, or reduce the risk of having a stroke. Pravastatin-DRLA lowers high blood cholesterol levels (Doctors call this hypercholesterolaemia). It is also used if your cholesterol levels are normal if you have had a heart attack or an episode of unstable angina. Pravastatin-DRLA is used to treat heterozygous familial hypercholesterolaemia in children and adolescent patients aged 8 years and older as an adjunct to diet and lifestyle changes. If you have had a heart attack, an episode of unstable angina or you have too much cholesterol in your blood, then you have an increased risk of a blood clot forming in your blood vessels and causing a blockage. Blood vessels that become blocked in this way can lead to further heart disease, angina or stroke. Pravastatin-DRLA may be used to lower lipids in heart or kidney transplant patients, who are also being given immunosuppressive medicine. Pravast اقرأ الوثيقة كاملة
Product Information Page 1 of 16 PRAVASTATIN–DRLA TABLETS NAME OF THE MEDICINE _Pravastatin Sodium _ Chemical name: Sodium (3R,5R)-3,5-dihydroxy-7[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8- [[(2S)-2-methylbutanoyl]oxy]-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]heptanoate Molecular formula: C 23 H 35 NaO 7 CAS number: 81131-70-6 Molecular weight: 446.5 Structural formula: CH 3 H OH H COONa H OH H HO H O O CH 3 H H 3 C H H DESCRIPTION Pravastatin is one of a new class of lipid-lowering compounds, the HMG-CoA reductase inhibitors, that reduce cholesterol biosynthesis. These agents are competitive inhibitors of 3- hydroxy-3-methylglutaryl- coenzyme A (HMG-CoA) reductase, the enzyme catalysing the early rate-limiting step in cholesterol biosynthesis, conversion of HMG-CoA to mevalonate. Pravastatin sodium is an odourless, white to off-white, fine or crystalline powder. It is a relatively polar hydrophilic compound with a partition coefficient (octanol/water) of 0.59 at a pH of 7.0. It is soluble in methanol and water (>300 mg/mL), slightly soluble in isopropanol, and practically insoluble in acetone, acetonitrile, chloroform, and ether. Pravastatin-DRLA tablets contain the following inactive ingredients: lactose, cellulose - microcrystalline, croscarmellose sodium, meglumine, crospovidone magnesium stearate, Opadry White YS- 1-7040. PHARMACOLOGY Pravastatin produces its lipid-lowering effect in two ways. First, as a consequence of its reversible inhibition of HMG-CoA reductase activity, it affects modest reductions in intracellular pools of cholesterol. This results in an increase in the number of LDL-receptors on cell surfaces and enhanced receptor- mediated catabolism and clearance of circulating LDL. Second, pravastatin inhibits LDL production by inhibiting hepatic synthesis of VLDL, the LDL precursor. Clinical and pathologic studies have shown that elevated levels of total cholesterol (Total-C), low density lipoprotein cholesterol (LDL-C) and apolipoprotein B ( a membrane transport complex for LDL) promote human athero اقرأ الوثيقة كاملة